期刊文献+

丙型肝炎病毒耐药相关变异对直接抗病毒药物疗效的影响 被引量:3

Effects of hepatitis C virus resistance associated variants on the efficacy of direct-acting antiviral agents
下载PDF
导出
摘要 随着直接抗病毒药物的不断更新与广泛应用,慢性丙型肝炎的治愈率显著提高。丙型肝炎病毒耐药相关变异直接影响抗病毒疗效和获得病毒学治愈的机会,已越来越受到关注。本文就丙型肝炎病毒耐药相关变异对直接抗病毒药物疗效的影响进行综述,以便更好地治疗丙型肝炎。 Along with the continuous renewal and wide use of direct-acting antiviral agents, the cure rate of chronic hepatitis C improved obviously. However, the resistance associated variants as well as their rapid emergence during incomplete drug-pressure greatly affect treatment outcome and the chances of virological cure. In this paper, the effects of drug resistance of hepatitis C virus on the efficacy of direct-acting antiviral agents were reviewed to facilitate better treatment on hepatitis C.
作者 全敏 邢卉春 QUAN Min;XING Hui-chun(Department of Hepatology Division 3,Beoing Ditan Hospital,Capital Medical University,Beijing 100015,China)
出处 《中国肝脏病杂志(电子版)》 CAS 2018年第3期32-36,共5页 Chinese Journal of Liver Diseases:Electronic Version
基金 北京市重点实验室开放研究课题(DTKF201704)
关键词 肝炎病毒 丙型 直接抗病毒药物 耐药相关变异 Hepatitis C virus Direct-acting antiviral agents Resistance associated variants
  • 相关文献

参考文献3

二级参考文献31

  • 1Susser S, Welsch C, Wang Y, et al. Characterization of resistance to the protease inhibitor boceprevir in hepatitis C virus -infected patients[J]. Hepatology, 2009, 50 (6): 1709-1718.
  • 2Hezode C, Forestier N, Dusheiko G, et al. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection[J]. N EnglJ Med, 2009, 360 (18) : 1839-1850.
  • 3Kieffer TL, Sarrazin C, MillerJS, et al. Telaprevir and pegylated interferon -alpha -2a inhibit wild -type and resistant genotype 1 hepatitis C virus replication in patients[J]. Hepatology, 2007, 46 ( 3 ): 631-639.
  • 4Sarrazin C, Kieffer TL, Bartels D, et al. Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir[J]. Gastroenterology, 2007,132(5): 1767-1777.
  • 5Kuntzen T, TimmJ , Berical A, et al. Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment?naive patients lJ]. Hepatology, 2008, 48(6): 1769 1778.
  • 6Cai Q, Zhao Z, Liu Y, et al. Comparison of three different HCV genotyping methods: Core, NS5B sequence analysis and line probe assay[J]. IntJ Mol Med, 2013, 31(2): 347-352.
  • 7McHutchison JG, Everson GT, Gordon SC, et al. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection [J]. N Engl J Med, 2009, 360(18) : 1827-1838.
  • 8Tong X, Bogen S, Chase R, et al. Characterization of resistance mutations against HCV ketoamide protease inhibitorsj]]. Antiviral Res, 2008, 77(3): 177-185.
  • 9Zhou Y, Bartels DJ, Hanzelka BL, et al. Phenotypic characterization of resistant Val36 variants of hepatitis C virus NS3- 4A serine protease [J]. Antimicrob Agents Chemother, 2008, 52(1) : 110-120.
  • 10Barbotte L, Ahmed - Belkacem A, Chevaliez S, et al. Characterization of V36c ,a novel amino acid substitution conferring hepatitis C virus (HCV) resistance to telaprevir, a potent pepti -domimetic inhibitor of HCV protease[J]. Antimicrob Agents Chemother, 2010, 54 (6): 2681-2683.

共引文献15

同被引文献11

引证文献3

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部